AstraZeneca: Dapagliflozin significantly reduces mortality in people with heart failure
ADC评论
August 30, 2022
On August 27, AstraZeneca updated the analysis results of the Phase III DAPA-HF and DELIVER studies, compared with placebo, dapagliflozin (brand name: Farxiga) can significantly
